Csl vifor and travere therapeutics announce european commission approves filspari® (sparsentan) for the treatment of iga nephropathy

First non-immunosuppressive therapy for the treatment of iga nephropathy (igan) approved in europe conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-iii protect trial st. gallen, switzerland and san diego, april 24, 2024 /prnewswire/ -- csl vifor and travere therapeutics, inc., (nasdaq: tvtx) today announced that the european commission has granted conditional marketing authorization (cma) for filspari (sparsentan) for the treatment of adults with primary igan with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).
TVTX Ratings Summary
TVTX Quant Ranking